

## Louisiana Medicaid Asthma/COPD – Inhaled Glucocorticoids

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request prior authorization for non-preferred inhaled glucocorticoids.

Additional Point-of-Sale edits may apply.

*These agents may have **Black Box Warnings** and/or may be subject to **Risk Evaluation and Mitigation Strategy (REMS)** under FDA safety regulations. Please refer to individual prescribing information for details.*

### Approval Criteria for Initial and Reauthorization Requests

- For budesonide/formoterol MDI (authorized generic for Symbicort®), there has been a treatment failure or intolerable side effect with or contraindication to brand Symbicort®; **OR**
- For fluticasone/salmeterol DPI (generic and authorized generic for Advair® Diskus®), there has been a treatment failure or intolerable side effect with or contraindication to brand Advair® Diskus®; **OR**
- For fluticasone/salmeterol MDI (authorized generic for Advair HFA®), there has been a treatment failure or intolerable side effect with or contraindication to brand Advair HFA®; **OR**
- ~~For fluticasone MDI (authorized generic for Flovent® HFA) — there has been a treatment failure or intolerable side effect with or contraindication to brand Flovent® HFA; **OR**~~
- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; **AND**
- Previous use of a preferred product - **ONE** of the following is required:
  - The recipient has had a *treatment failure* with at least one preferred product; **OR**
  - The recipient has had an *intolerable side effect* to at least one preferred product; **OR**
  - The recipient has *documented contraindication(s)* to all of the preferred products that are appropriate to use for the condition being treated; **OR**
  - There is *no preferred product that is appropriate* to use for the condition being treated; **AND**
- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not be receiving the requested medication in combination with any other medication that is contraindicated or not recommended per FDA labeling.

**Duration of initial and reauthorization approval: 12 months**

### References

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.;  
<https://www.clinicalkey.com/pharmacology/>

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 10e New York, NY: McGraw-Hill;  
<https://accesspharmacy.mhmedical.com/book.aspx?bookid=1861>

<b>Revision / Date</b>	<b>Implementation Date</b>
Single PDL Implementation	May 2019
Separated “Select Therapeutic Classes Not Established” into individual therapeutic class documents / November 2019	January 2020
Added preferred brand wording for Advair Diskus® and Symbicort®, added references / November 2020	January 2021
Formatting changes, removed specific references / September 2021	January 2022
Added wording for use of Flovent® HFA / November 2022	January 2023
<u>Added wording for use of Advair HFA®, removed wording for use of Flovent® HFA / October 2023</u>	<u>January 2024</u>